Dedifferentiated, Programmable Stem Cells of Monocytic Origin, and Their Production and Use

Abstract

The invention relates to the production of adult dedifferentiated, programmable stem cells from human monocytes by cultivation of monocytes in a culture medium which contains M-CSF and IL-3. The invention further relates to pharmaceutical preparations, which contain the dedifferentiated, programmable stem cells and the use of these stem cells for the production of target cells and target tissue.

1 - 34 . (canceled) 
   
   
       35 . A cell expressing insulin and a membrane-associated CD14 antigen. 
   
   
       36 . The cell of  claim 35 , wherein said cell is isolated in a medium. 
   
   
       37 . The cell of  claim 36 , wherein said medium comprises epidermal growth factor, hepatocyte growth factor, nicotinamide and glucose. 
   
   
       38 . The cell of  claim 35 , further comprising a medium. 
   
   
       39 . The cell of  claim 38 , wherein said medium comprises epidermal growth factor and hepatocyte growth factor. 
   
   
       40 . An insulin-producing cell derived from a dedifferentiated, programmable cell derived from a monocyte that expresses a CD14 antigen and a CD90 antigen. 
   
   
       41 . The insulin-producing cell of  claim 40 , wherein said insulin-producing cell expresses CD14. 
   
   
       42 . The insulin-producing cell of  claim 40 , wherein said insulin-producing cell is isolated in a medium. 
   
   
       43 . The insulin-producing cell of  claim 42 , wherein said medium comprises epidermal growth factor, hepatocyte growth factor, nicotinamide and glucose. 
   
   
       44 . The insulin-producing cell of  claim 40 , further comprising a medium. 
   
   
       45 . The insulin-producing cell of  claim 44 , wherein said medium comprises epidermal growth factor and hepatocyte growth factor. 
   
   
       46 . A pharmaceutical construct comprising the cell of  claim 35 . 
   
   
       47 . A pharmaceutical construct comprising the cell of  claim 40 .